Systemic therapy is used in patients who have the following: Infection by L braziliensis or related organisms associated with mucosal leishmaniasis Complex cutaneous leishmaniasis with multiple, large, widespread, or disfiguring lesions Compromised cell-mediated immunity In the US, systemic options include liposomal amphotericin B, miltefosine, and amphotericin B deoxycholate.